Results 51 to 60 of about 3,690 (153)

Discrepancies in Beta‐Lactam Antibiotics Cross‐Reactivity: Implications for Clinical Practice

Allergy, Volume 80, Issue 11, Page 3108-3114, November 2025.
Four studies previously published on beta‐lactam antibiotics cross‐reactivity were compared head‐to‐head. These studies covered 51 antibiotics, theoretically leading to 2550 potential recommendations regarding alternatives in case of specific allergies. The studies analysed different sets of beta‐lactam antibiotics.
Evelien Maria Hutten, Maja Bulatović Ćalasan, Jason Anthony Trubiano, Rick Gert‐Jan Pleijhuis, Ingrid Terreehorst   +4 more
wiley   +1 more source

Pre‐Exposure to α‐Linolenic Acid Reduces Virulence of Cronobacter sakazakii in Galleria mellonella Infection Model

Journal of Food Safety, Volume 45, Issue 5, October 2025.
Pre‐exposure of Cronobacter sakazakii to α‐linolenic acid (ALA) resulted in reduced virulence mechanisms as shown in an in vivo G. mellonella infection model. Additionally, the same treatment did not alter antimicrobial resistance of C. sakazakii. ALA shows potential for implementation as a control method for use in food production.
Katie Phair, Aaron Curtis, Sónia G. Pereira, Carmel Kealey, Kevin Kavanagh, Damien Brady   +5 more
wiley   +1 more source

Unveiling Novel Arginase Inhibitors for Cutaneous Leishmaniasis Using Drug Repurposing and Virtual Screening Approaches

Journal of Cellular Biochemistry, Volume 126, Issue 8, August 2025.
ABSTRACT Leishmaniasis is a neglected tropical disease with a significant global health burden, particularly in developing countries, where it accounts for approximately 1.6 million new infections annually. Current therapeutic options are limited by severe adverse effects, toxicity, and drug resistance, highlighting the urgent need for novel treatment ...
Eduarda Moreira Barreto, Gabriel Rodrigues Coutinho Pereira, Isadora de Salles Arêas, Júlia Mendes Fortes, Alessandra da Silva Domingos, Lucio Mendes Cabral, Carlos Rangel Rodrigues, Alessandra Mendonça Teles de Souza, Barbara de Azevedo Abrahim‐Vieira   +8 more
wiley   +1 more source

Investigation on Klebsiella pneumoniae in the field of extracellular vesicles

Interdisciplinary Medicine, Volume 3, Issue 4, July 2025.
The role of extracellular vesicles in the pathogenicity and antibiotic resistance, as well as treatment and prevention of Klebsiella pneumoniae. Abstract Klebsiella pneumoniae (KP), recognized for its pronounced antibiotic resistance, is a prevalent agent of nosocomial infections such as hospital‐acquired pneumonia.
Junwei Wu, Yuheng Liu, Jin Su, Yi Yang, Haiyi Deng, Yilin Yang, Mengxi Yanglan, Xinyi Wu, Shiqi Luo, Yao Liao, Lifu Wang   +10 more
wiley   +1 more source

In vitro activity of cefiderocol against nosocomial Acinetobacter baumannii

Microbiology Spectrum
The emergence and spread of third-/fourth-generation cephalosporin and/or carbapenem-resistant Acinetobacter baumannii have become a significant global public health concern, making new treatment alternatives necessary.
Barbara Ymaña, Rocío Egoávil-Espejo, Rosario Huerto-Huánuco, Rosario Oporto-Llerena, Carla A. Alonso, Angie K. Castillo, Luciano A. Palomino-Kobayashi, Carmen Valera-Krumdieck, Gabriela Soza, Tamin Ortiz-Gomez, Patricia Gonzales, María López, Gina Salvador-Luján, Beatriz Rojo-Bezares, Martin Casapia, Paula Toledano, Joseph Pinto, Maria Ramos Chirinos, Yolanda Sáenz, Maria J. Pons, Joaquim Ruiz   +20 more
doaj   +1 more source

Pharmacokinetic and pharmacodynamic evaluation of sulbactam‐durlobactam in a critically ill patient on continuous venovenous hemofiltration infected with carbapenem‐resistant Acinetobacter baumannii‐calcoaceticus complex

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 45, Issue 7, Page 396-402, July 2025.
Abstract Background Drug databases currently do not provide dosing guidance for sulbactam‐durlobactam in continuous renal replacement therapy. Herein, we present the first in vivo pharmacokinetic (PK) evaluation of sulbactam‐durlobactam during continuous venovenous hemofiltration (CVVH) in a patient with carbapenem‐resistant Acinetobacter baumannii ...
Wesley D. Kufel, Nabil Zeineddine, Aliaa Fouad, Hanna F. Roenfanz, Ryan K. Shields, Ellen G. Kline, Jameson Warner, Kathleen Hanrahan, Joseph L. Kuti   +8 more
wiley   +1 more source

Activity of cefiderocol against Pseudomonas aeruginosa from the USA and Europe (2020–2023) with difficult-to-treat resistance phenotype, including those nonsusceptible to recently developed β-lactam/β-lactamase inhibitor combinations: results from the SENTRY antimicrobial surveillance program

Microbiology Spectrum
Cefiderocol and the β-lactam/β-lactamase inhibitor (BL-BLI) combinations ceftazidime-avibactam (CAZ-AVI), imipenem-relebactam (IMI-REL), and ceftolozane-tazobactam (TOL-TAZ) are recommended for the treatment of difficult-to-treat resistance (DTR ...
John H. Kimbrough, Maura H. Karr, Sean T. Nguyen, Boudewijn L. M. DeJonge, Chris Longshaw, Miki Takemura, Yoshinori Yamano, Mariana Castanheira, Rodrigo E. Mendes   +8 more
doaj   +1 more source

Pharmacokinetics of continuous infusion ceftolozane/tazobactam in two patients with extensive total body surface area burns

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 45, Issue 6, Page 386-392, June 2025.
Abstract Introduction Treatment of infections in patients with burn injuries is challenging due to altered antimicrobial pharmacokinetics. Continuous infusion β‐lactam therapy may be a useful antimicrobial stewardship strategy to improve pharmacodynamic target attainment in this population.
Jay D. Olivet, Megan Amerson‐Brown, Juan J. Calix, Emma Graffice, Tyson Kilpatrick, Hanna F. Roenfanz, David P. Nicolau, Joseph L. Kuti, Matthew L. Brown   +8 more
wiley   +1 more source

Experimental evolution of cefiderocol resistance in Pseudomonas aeruginosa

Heliyon
Cefiderocol is a novel and promising cephalosporin approved for treating severe infections caused by Gram-negative bacteria with limited therapeutic options. One of the primary targets of cefiderocol is Pseudomonas aeruginosa, a significant opportunistic
Igor Chebotar, Konstantin Kuleshov, Julia Bocharova, Nikolay Mayanskiy   +3 more
doaj   +1 more source

Metal‐Catalyzed Cross‐Coupling for the Synthesis of β‐Lactam Drugs and Related Chemical Probes

ChemMedChem, Volume 20, Issue 9, May 5, 2025.
This review focus on the use of transition metal cross‐coupling strategies for the synthesis of beta‐lactam derivatives. This manuscript encompasses the seminal studies for the synthesis of antibiotics up to the current need of accessing specific probes that are crucial for the detection of resistances.
Jules Bresson, Katie Burke, Mélanie Ethève‐Quelquejeu, Laura Iannazzo, Kevin Cariou   +4 more
wiley   +1 more source